HIV Infections trials in Denmark

Showing 26 to 41 of 41. Each trial links to its page on Pharma Observatory.

• TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients NCT00110877·Phase 3·Completed·Tibotec Pharmaceuticals, Ireland·Started 2005
• The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients NCT00119769·Phase 4·Completed·Hvidovre University Hospital·Started 2005
• GW873140 In Combination With Kaletra In HIV Infected Subjects NCT00102778·Phase 2·Terminated·ViiV Healthcare·Started 2004
• An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. NCT00933205·Expanded access·Approved for marketing·Boehringer Ingelheim·Started 2004
• Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients NCT00135460·Phase 4·Unknown status·Danish HIV Research Group·Started 2003
• Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection NCT00062660·Expanded access·Approved for marketing·Boehringer Ingelheim·Started 2003
• Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2) NCT00144170·Phase 3·Completed·Boehringer Ingelheim·Started 2003
• Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients NCT00056641·Phase 2·Completed·Boehringer Ingelheim·Started 2003
• Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2 NCT00050726·Phase 2·Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Started 2001
• Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects NCT00146328·Phase 2/3·Completed·Boehringer Ingelheim·Started 2001
• An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy NCT00004978·Phase 3·Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Started 2000
• A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy NCT00004583·Phase 3·Completed·Abbott·Started 1999
• A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients NCT00001038·Phase 3·Completed·National Institute of Allergy and Infectious Diseases (NIAID)
• A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment NCT00004581·Phase 3·Completed·Abbott
• TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. NCT00245739·Expanded access·Approved for marketing·Tibotec Pharmaceuticals, Ireland
• Collection of Blood Samples From SMART Study Participants for Future Genetic Studies NCT00377169·Observational·Completed·National Institute of Allergy and Infectious Diseases (NIAID)